PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may prevent lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib can help prevent T-cell lymphoma from returning and reduce graft-versus-host disease (GVHD) after a stem cell transplant. About 44 adults with T-cell lymphoma who are in remission after transplant will take ruxolitinib as a maintenanc…
Matched conditions: PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated May 26, 2026 03:43 UTC
-
New combo therapy offers hope for rare skin cancer patients
Disease control Recruiting nowThis study tests a new combination treatment for a rare type of skin lymphoma called erythrodermic cutaneous T-cell lymphoma (CTCL). The treatment combines a light-based blood therapy (ECP) with a targeted antibody drug (mogamulizumab) to kill cancer cells and boost the immune sy…
Matched conditions: PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug Q702 aims to boost immune system against Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…
Matched conditions: PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:47 UTC